Global Psoriasis Treatment

Psoriasis Treatment Comprehensive Study by Type (Psoriatic Arthritis, Plaque Psoriasis, Others), Route of Administration (Oral, Parenteral, Topical), Distribution Channel (Hospital Pharmacies, Online pharmacies, Retail Pharmacies), Drug Class (Interleukins, TNF Inhibitors, Others) Players and Region - Global Market Outlook to 2028

Psoriasis Treatment Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Psoriasis Treatment Market Scope
Psoriasis is a skin illness that is characterized as an autoimmune inflammatory disorder and is brought on by an excess of tissue cells in the skin. Over time, the patient experiences symptoms such excessive dryness, itching, bleeding, and local discomfort. In severe cases, the patient feels prickling pain and irritation over the skin. Plaque psoriasis and psoriatic arthritis are two subtypes of the illness. Patients with psoriatic arthritis frequently also experience skin problems, discomfort in the joints, and other symptoms.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledJohnson & Johnson Services, Inc. (U.S.), Pfizer Inc. (U.S.), AbbVie Inc. (U.S.), Novartis AG (Switzerland), LEO Pharma A/S (Denmark), Merck & Co., Inc. (U.S.), UCB S.A. (Belgium), Sun Pharmaceutical Industries Ltd. (India), Amgen Inc. (U.S.), Eli Lilly and Company (U.S.) and Evelo Biosciences, Inc. (U.S.)
CAGR%


The competitive landscape for the psoriasis treatment market gives information by competitor. The company's financials, revenue generated, market potential, investment in R&D, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance are among the details that are included. The psoriasis treatment market is the sole area on which the aforementioned data points are focused. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Psoriasis Treatment market throughout the predicted period.

Johnson & Johnson Services, Inc. (U.S.), Pfizer Inc. (U.S.), AbbVie Inc. (U.S.), Novartis AG (Switzerland), LEO Pharma A/S (Denmark), Merck & Co., Inc. (U.S.), UCB S.A. (Belgium), Sun Pharmaceutical Industries Ltd. (India), Amgen Inc. (U.S.), Eli Lilly and Company (U.S.) and Evelo Biosciences, Inc. (U.S.) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Psoriasis Treatment market by Type and Region with country level break-up.

On the basis of geography, the market of Psoriasis Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2022.

Market Leaders and their expansionary development strategies
In 2021 – The strategic partnership between LEO Parma and Veeva Systems was made public in order to perform clinical trials and improve the procedure's outcomes, and In 2021 – The European Commission has given AbbVie Limited clearance for the subcutaneous injectable SKYRIZI. It is anticipated that this medicine will treat active psoriatic arthritis.



Influencing Trend:
Surge in initiatives by government and Demand for psoriasis medicines in emerging economies

Market Growth Drivers:
The high prevalence of skin disorders in the developed nations and Rapidly increasing geriatric population

Challenges:
The long-term treatment which is associated with these skin disorders amounts to a huge amount over the period of time

Restraints:
The lack of disposable income available with the people

Opportunities:
The surge in the collaborations among manufacturers, Increase in the awareness regarding treatment and The rise in disease burden

Report Objectives / Segmentation Covered

By Type
  • Psoriatic Arthritis
  • Plaque Psoriasis
  • Others
By Route of Administration
  • Oral
  • Parenteral
  • Topical

By Distribution Channel
  • Hospital Pharmacies
  • Online pharmacies
  • Retail Pharmacies

By Drug Class
  • Interleukins
  • TNF Inhibitors
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The high prevalence of skin disorders in the developed nations
      • 3.2.2. Rapidly increasing geriatric population
    • 3.3. Market Challenges
      • 3.3.1. The long-term treatment which is associated with these skin disorders amounts to a huge amount over the period of time
    • 3.4. Market Trends
      • 3.4.1. Surge in initiatives by government
      • 3.4.2. Demand for psoriasis medicines in emerging economies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Psoriasis Treatment, by Type, Route of Administration, Distribution Channel, Drug Class and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Psoriasis Treatment (Value)
      • 5.2.1. Global Psoriasis Treatment by: Type (Value)
        • 5.2.1.1. Psoriatic Arthritis
        • 5.2.1.2. Plaque Psoriasis
        • 5.2.1.3. Others
      • 5.2.2. Global Psoriasis Treatment by: Route of Administration (Value)
        • 5.2.2.1. Oral
        • 5.2.2.2. Parenteral
        • 5.2.2.3. Topical
      • 5.2.3. Global Psoriasis Treatment by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Online pharmacies
        • 5.2.3.3. Retail Pharmacies
      • 5.2.4. Global Psoriasis Treatment by: Drug Class (Value)
        • 5.2.4.1. Interleukins
        • 5.2.4.2. TNF Inhibitors
        • 5.2.4.3. Others
      • 5.2.5. Global Psoriasis Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Psoriasis Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Johnson & Johnson Services, Inc. (U.S.)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer Inc. (U.S.)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. AbbVie Inc. (U.S.)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novartis AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. LEO Pharma A/S (Denmark)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck & Co., Inc. (U.S.)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. UCB S.A. (Belgium)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sun Pharmaceutical Industries Ltd. (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Amgen Inc. (U.S.)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Eli Lilly and Company (U.S.)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Evelo Biosciences, Inc. (U.S.)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Psoriasis Treatment Sale, by Type, Route of Administration, Distribution Channel, Drug Class and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Psoriasis Treatment (Value)
      • 7.2.1. Global Psoriasis Treatment by: Type (Value)
        • 7.2.1.1. Psoriatic Arthritis
        • 7.2.1.2. Plaque Psoriasis
        • 7.2.1.3. Others
      • 7.2.2. Global Psoriasis Treatment by: Route of Administration (Value)
        • 7.2.2.1. Oral
        • 7.2.2.2. Parenteral
        • 7.2.2.3. Topical
      • 7.2.3. Global Psoriasis Treatment by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Online pharmacies
        • 7.2.3.3. Retail Pharmacies
      • 7.2.4. Global Psoriasis Treatment by: Drug Class (Value)
        • 7.2.4.1. Interleukins
        • 7.2.4.2. TNF Inhibitors
        • 7.2.4.3. Others
      • 7.2.5. Global Psoriasis Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Psoriasis Treatment: by Type(USD Million)
  • Table 2. Psoriasis Treatment Psoriatic Arthritis , by Region USD Million (2017-2022)
  • Table 3. Psoriasis Treatment Plaque Psoriasis , by Region USD Million (2017-2022)
  • Table 4. Psoriasis Treatment Others , by Region USD Million (2017-2022)
  • Table 5. Psoriasis Treatment: by Route of Administration(USD Million)
  • Table 6. Psoriasis Treatment Oral , by Region USD Million (2017-2022)
  • Table 7. Psoriasis Treatment Parenteral , by Region USD Million (2017-2022)
  • Table 8. Psoriasis Treatment Topical , by Region USD Million (2017-2022)
  • Table 9. Psoriasis Treatment: by Distribution Channel(USD Million)
  • Table 10. Psoriasis Treatment Hospital Pharmacies , by Region USD Million (2017-2022)
  • Table 11. Psoriasis Treatment Online pharmacies , by Region USD Million (2017-2022)
  • Table 12. Psoriasis Treatment Retail Pharmacies , by Region USD Million (2017-2022)
  • Table 13. Psoriasis Treatment: by Drug Class(USD Million)
  • Table 14. Psoriasis Treatment Interleukins , by Region USD Million (2017-2022)
  • Table 15. Psoriasis Treatment TNF Inhibitors , by Region USD Million (2017-2022)
  • Table 16. Psoriasis Treatment Others , by Region USD Million (2017-2022)
  • Table 17. South America Psoriasis Treatment, by Country USD Million (2017-2022)
  • Table 18. South America Psoriasis Treatment, by Type USD Million (2017-2022)
  • Table 19. South America Psoriasis Treatment, by Route of Administration USD Million (2017-2022)
  • Table 20. South America Psoriasis Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 21. South America Psoriasis Treatment, by Drug Class USD Million (2017-2022)
  • Table 22. Brazil Psoriasis Treatment, by Type USD Million (2017-2022)
  • Table 23. Brazil Psoriasis Treatment, by Route of Administration USD Million (2017-2022)
  • Table 24. Brazil Psoriasis Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 25. Brazil Psoriasis Treatment, by Drug Class USD Million (2017-2022)
  • Table 26. Argentina Psoriasis Treatment, by Type USD Million (2017-2022)
  • Table 27. Argentina Psoriasis Treatment, by Route of Administration USD Million (2017-2022)
  • Table 28. Argentina Psoriasis Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 29. Argentina Psoriasis Treatment, by Drug Class USD Million (2017-2022)
  • Table 30. Rest of South America Psoriasis Treatment, by Type USD Million (2017-2022)
  • Table 31. Rest of South America Psoriasis Treatment, by Route of Administration USD Million (2017-2022)
  • Table 32. Rest of South America Psoriasis Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 33. Rest of South America Psoriasis Treatment, by Drug Class USD Million (2017-2022)
  • Table 34. Asia Pacific Psoriasis Treatment, by Country USD Million (2017-2022)
  • Table 35. Asia Pacific Psoriasis Treatment, by Type USD Million (2017-2022)
  • Table 36. Asia Pacific Psoriasis Treatment, by Route of Administration USD Million (2017-2022)
  • Table 37. Asia Pacific Psoriasis Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 38. Asia Pacific Psoriasis Treatment, by Drug Class USD Million (2017-2022)
  • Table 39. China Psoriasis Treatment, by Type USD Million (2017-2022)
  • Table 40. China Psoriasis Treatment, by Route of Administration USD Million (2017-2022)
  • Table 41. China Psoriasis Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 42. China Psoriasis Treatment, by Drug Class USD Million (2017-2022)
  • Table 43. Japan Psoriasis Treatment, by Type USD Million (2017-2022)
  • Table 44. Japan Psoriasis Treatment, by Route of Administration USD Million (2017-2022)
  • Table 45. Japan Psoriasis Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 46. Japan Psoriasis Treatment, by Drug Class USD Million (2017-2022)
  • Table 47. India Psoriasis Treatment, by Type USD Million (2017-2022)
  • Table 48. India Psoriasis Treatment, by Route of Administration USD Million (2017-2022)
  • Table 49. India Psoriasis Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 50. India Psoriasis Treatment, by Drug Class USD Million (2017-2022)
  • Table 51. South Korea Psoriasis Treatment, by Type USD Million (2017-2022)
  • Table 52. South Korea Psoriasis Treatment, by Route of Administration USD Million (2017-2022)
  • Table 53. South Korea Psoriasis Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 54. South Korea Psoriasis Treatment, by Drug Class USD Million (2017-2022)
  • Table 55. Taiwan Psoriasis Treatment, by Type USD Million (2017-2022)
  • Table 56. Taiwan Psoriasis Treatment, by Route of Administration USD Million (2017-2022)
  • Table 57. Taiwan Psoriasis Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 58. Taiwan Psoriasis Treatment, by Drug Class USD Million (2017-2022)
  • Table 59. Australia Psoriasis Treatment, by Type USD Million (2017-2022)
  • Table 60. Australia Psoriasis Treatment, by Route of Administration USD Million (2017-2022)
  • Table 61. Australia Psoriasis Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 62. Australia Psoriasis Treatment, by Drug Class USD Million (2017-2022)
  • Table 63. Rest of Asia-Pacific Psoriasis Treatment, by Type USD Million (2017-2022)
  • Table 64. Rest of Asia-Pacific Psoriasis Treatment, by Route of Administration USD Million (2017-2022)
  • Table 65. Rest of Asia-Pacific Psoriasis Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 66. Rest of Asia-Pacific Psoriasis Treatment, by Drug Class USD Million (2017-2022)
  • Table 67. Europe Psoriasis Treatment, by Country USD Million (2017-2022)
  • Table 68. Europe Psoriasis Treatment, by Type USD Million (2017-2022)
  • Table 69. Europe Psoriasis Treatment, by Route of Administration USD Million (2017-2022)
  • Table 70. Europe Psoriasis Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 71. Europe Psoriasis Treatment, by Drug Class USD Million (2017-2022)
  • Table 72. Germany Psoriasis Treatment, by Type USD Million (2017-2022)
  • Table 73. Germany Psoriasis Treatment, by Route of Administration USD Million (2017-2022)
  • Table 74. Germany Psoriasis Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 75. Germany Psoriasis Treatment, by Drug Class USD Million (2017-2022)
  • Table 76. France Psoriasis Treatment, by Type USD Million (2017-2022)
  • Table 77. France Psoriasis Treatment, by Route of Administration USD Million (2017-2022)
  • Table 78. France Psoriasis Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 79. France Psoriasis Treatment, by Drug Class USD Million (2017-2022)
  • Table 80. Italy Psoriasis Treatment, by Type USD Million (2017-2022)
  • Table 81. Italy Psoriasis Treatment, by Route of Administration USD Million (2017-2022)
  • Table 82. Italy Psoriasis Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 83. Italy Psoriasis Treatment, by Drug Class USD Million (2017-2022)
  • Table 84. United Kingdom Psoriasis Treatment, by Type USD Million (2017-2022)
  • Table 85. United Kingdom Psoriasis Treatment, by Route of Administration USD Million (2017-2022)
  • Table 86. United Kingdom Psoriasis Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 87. United Kingdom Psoriasis Treatment, by Drug Class USD Million (2017-2022)
  • Table 88. Netherlands Psoriasis Treatment, by Type USD Million (2017-2022)
  • Table 89. Netherlands Psoriasis Treatment, by Route of Administration USD Million (2017-2022)
  • Table 90. Netherlands Psoriasis Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 91. Netherlands Psoriasis Treatment, by Drug Class USD Million (2017-2022)
  • Table 92. Rest of Europe Psoriasis Treatment, by Type USD Million (2017-2022)
  • Table 93. Rest of Europe Psoriasis Treatment, by Route of Administration USD Million (2017-2022)
  • Table 94. Rest of Europe Psoriasis Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 95. Rest of Europe Psoriasis Treatment, by Drug Class USD Million (2017-2022)
  • Table 96. MEA Psoriasis Treatment, by Country USD Million (2017-2022)
  • Table 97. MEA Psoriasis Treatment, by Type USD Million (2017-2022)
  • Table 98. MEA Psoriasis Treatment, by Route of Administration USD Million (2017-2022)
  • Table 99. MEA Psoriasis Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 100. MEA Psoriasis Treatment, by Drug Class USD Million (2017-2022)
  • Table 101. Middle East Psoriasis Treatment, by Type USD Million (2017-2022)
  • Table 102. Middle East Psoriasis Treatment, by Route of Administration USD Million (2017-2022)
  • Table 103. Middle East Psoriasis Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 104. Middle East Psoriasis Treatment, by Drug Class USD Million (2017-2022)
  • Table 105. Africa Psoriasis Treatment, by Type USD Million (2017-2022)
  • Table 106. Africa Psoriasis Treatment, by Route of Administration USD Million (2017-2022)
  • Table 107. Africa Psoriasis Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 108. Africa Psoriasis Treatment, by Drug Class USD Million (2017-2022)
  • Table 109. North America Psoriasis Treatment, by Country USD Million (2017-2022)
  • Table 110. North America Psoriasis Treatment, by Type USD Million (2017-2022)
  • Table 111. North America Psoriasis Treatment, by Route of Administration USD Million (2017-2022)
  • Table 112. North America Psoriasis Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 113. North America Psoriasis Treatment, by Drug Class USD Million (2017-2022)
  • Table 114. United States Psoriasis Treatment, by Type USD Million (2017-2022)
  • Table 115. United States Psoriasis Treatment, by Route of Administration USD Million (2017-2022)
  • Table 116. United States Psoriasis Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 117. United States Psoriasis Treatment, by Drug Class USD Million (2017-2022)
  • Table 118. Canada Psoriasis Treatment, by Type USD Million (2017-2022)
  • Table 119. Canada Psoriasis Treatment, by Route of Administration USD Million (2017-2022)
  • Table 120. Canada Psoriasis Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 121. Canada Psoriasis Treatment, by Drug Class USD Million (2017-2022)
  • Table 122. Mexico Psoriasis Treatment, by Type USD Million (2017-2022)
  • Table 123. Mexico Psoriasis Treatment, by Route of Administration USD Million (2017-2022)
  • Table 124. Mexico Psoriasis Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 125. Mexico Psoriasis Treatment, by Drug Class USD Million (2017-2022)
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Psoriasis Treatment: by Type(USD Million)
  • Table 138. Psoriasis Treatment Psoriatic Arthritis , by Region USD Million (2023-2028)
  • Table 139. Psoriasis Treatment Plaque Psoriasis , by Region USD Million (2023-2028)
  • Table 140. Psoriasis Treatment Others , by Region USD Million (2023-2028)
  • Table 141. Psoriasis Treatment: by Route of Administration(USD Million)
  • Table 142. Psoriasis Treatment Oral , by Region USD Million (2023-2028)
  • Table 143. Psoriasis Treatment Parenteral , by Region USD Million (2023-2028)
  • Table 144. Psoriasis Treatment Topical , by Region USD Million (2023-2028)
  • Table 145. Psoriasis Treatment: by Distribution Channel(USD Million)
  • Table 146. Psoriasis Treatment Hospital Pharmacies , by Region USD Million (2023-2028)
  • Table 147. Psoriasis Treatment Online pharmacies , by Region USD Million (2023-2028)
  • Table 148. Psoriasis Treatment Retail Pharmacies , by Region USD Million (2023-2028)
  • Table 149. Psoriasis Treatment: by Drug Class(USD Million)
  • Table 150. Psoriasis Treatment Interleukins , by Region USD Million (2023-2028)
  • Table 151. Psoriasis Treatment TNF Inhibitors , by Region USD Million (2023-2028)
  • Table 152. Psoriasis Treatment Others , by Region USD Million (2023-2028)
  • Table 153. South America Psoriasis Treatment, by Country USD Million (2023-2028)
  • Table 154. South America Psoriasis Treatment, by Type USD Million (2023-2028)
  • Table 155. South America Psoriasis Treatment, by Route of Administration USD Million (2023-2028)
  • Table 156. South America Psoriasis Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 157. South America Psoriasis Treatment, by Drug Class USD Million (2023-2028)
  • Table 158. Brazil Psoriasis Treatment, by Type USD Million (2023-2028)
  • Table 159. Brazil Psoriasis Treatment, by Route of Administration USD Million (2023-2028)
  • Table 160. Brazil Psoriasis Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 161. Brazil Psoriasis Treatment, by Drug Class USD Million (2023-2028)
  • Table 162. Argentina Psoriasis Treatment, by Type USD Million (2023-2028)
  • Table 163. Argentina Psoriasis Treatment, by Route of Administration USD Million (2023-2028)
  • Table 164. Argentina Psoriasis Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 165. Argentina Psoriasis Treatment, by Drug Class USD Million (2023-2028)
  • Table 166. Rest of South America Psoriasis Treatment, by Type USD Million (2023-2028)
  • Table 167. Rest of South America Psoriasis Treatment, by Route of Administration USD Million (2023-2028)
  • Table 168. Rest of South America Psoriasis Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 169. Rest of South America Psoriasis Treatment, by Drug Class USD Million (2023-2028)
  • Table 170. Asia Pacific Psoriasis Treatment, by Country USD Million (2023-2028)
  • Table 171. Asia Pacific Psoriasis Treatment, by Type USD Million (2023-2028)
  • Table 172. Asia Pacific Psoriasis Treatment, by Route of Administration USD Million (2023-2028)
  • Table 173. Asia Pacific Psoriasis Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 174. Asia Pacific Psoriasis Treatment, by Drug Class USD Million (2023-2028)
  • Table 175. China Psoriasis Treatment, by Type USD Million (2023-2028)
  • Table 176. China Psoriasis Treatment, by Route of Administration USD Million (2023-2028)
  • Table 177. China Psoriasis Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 178. China Psoriasis Treatment, by Drug Class USD Million (2023-2028)
  • Table 179. Japan Psoriasis Treatment, by Type USD Million (2023-2028)
  • Table 180. Japan Psoriasis Treatment, by Route of Administration USD Million (2023-2028)
  • Table 181. Japan Psoriasis Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 182. Japan Psoriasis Treatment, by Drug Class USD Million (2023-2028)
  • Table 183. India Psoriasis Treatment, by Type USD Million (2023-2028)
  • Table 184. India Psoriasis Treatment, by Route of Administration USD Million (2023-2028)
  • Table 185. India Psoriasis Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 186. India Psoriasis Treatment, by Drug Class USD Million (2023-2028)
  • Table 187. South Korea Psoriasis Treatment, by Type USD Million (2023-2028)
  • Table 188. South Korea Psoriasis Treatment, by Route of Administration USD Million (2023-2028)
  • Table 189. South Korea Psoriasis Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 190. South Korea Psoriasis Treatment, by Drug Class USD Million (2023-2028)
  • Table 191. Taiwan Psoriasis Treatment, by Type USD Million (2023-2028)
  • Table 192. Taiwan Psoriasis Treatment, by Route of Administration USD Million (2023-2028)
  • Table 193. Taiwan Psoriasis Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 194. Taiwan Psoriasis Treatment, by Drug Class USD Million (2023-2028)
  • Table 195. Australia Psoriasis Treatment, by Type USD Million (2023-2028)
  • Table 196. Australia Psoriasis Treatment, by Route of Administration USD Million (2023-2028)
  • Table 197. Australia Psoriasis Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 198. Australia Psoriasis Treatment, by Drug Class USD Million (2023-2028)
  • Table 199. Rest of Asia-Pacific Psoriasis Treatment, by Type USD Million (2023-2028)
  • Table 200. Rest of Asia-Pacific Psoriasis Treatment, by Route of Administration USD Million (2023-2028)
  • Table 201. Rest of Asia-Pacific Psoriasis Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 202. Rest of Asia-Pacific Psoriasis Treatment, by Drug Class USD Million (2023-2028)
  • Table 203. Europe Psoriasis Treatment, by Country USD Million (2023-2028)
  • Table 204. Europe Psoriasis Treatment, by Type USD Million (2023-2028)
  • Table 205. Europe Psoriasis Treatment, by Route of Administration USD Million (2023-2028)
  • Table 206. Europe Psoriasis Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 207. Europe Psoriasis Treatment, by Drug Class USD Million (2023-2028)
  • Table 208. Germany Psoriasis Treatment, by Type USD Million (2023-2028)
  • Table 209. Germany Psoriasis Treatment, by Route of Administration USD Million (2023-2028)
  • Table 210. Germany Psoriasis Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 211. Germany Psoriasis Treatment, by Drug Class USD Million (2023-2028)
  • Table 212. France Psoriasis Treatment, by Type USD Million (2023-2028)
  • Table 213. France Psoriasis Treatment, by Route of Administration USD Million (2023-2028)
  • Table 214. France Psoriasis Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 215. France Psoriasis Treatment, by Drug Class USD Million (2023-2028)
  • Table 216. Italy Psoriasis Treatment, by Type USD Million (2023-2028)
  • Table 217. Italy Psoriasis Treatment, by Route of Administration USD Million (2023-2028)
  • Table 218. Italy Psoriasis Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 219. Italy Psoriasis Treatment, by Drug Class USD Million (2023-2028)
  • Table 220. United Kingdom Psoriasis Treatment, by Type USD Million (2023-2028)
  • Table 221. United Kingdom Psoriasis Treatment, by Route of Administration USD Million (2023-2028)
  • Table 222. United Kingdom Psoriasis Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 223. United Kingdom Psoriasis Treatment, by Drug Class USD Million (2023-2028)
  • Table 224. Netherlands Psoriasis Treatment, by Type USD Million (2023-2028)
  • Table 225. Netherlands Psoriasis Treatment, by Route of Administration USD Million (2023-2028)
  • Table 226. Netherlands Psoriasis Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 227. Netherlands Psoriasis Treatment, by Drug Class USD Million (2023-2028)
  • Table 228. Rest of Europe Psoriasis Treatment, by Type USD Million (2023-2028)
  • Table 229. Rest of Europe Psoriasis Treatment, by Route of Administration USD Million (2023-2028)
  • Table 230. Rest of Europe Psoriasis Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 231. Rest of Europe Psoriasis Treatment, by Drug Class USD Million (2023-2028)
  • Table 232. MEA Psoriasis Treatment, by Country USD Million (2023-2028)
  • Table 233. MEA Psoriasis Treatment, by Type USD Million (2023-2028)
  • Table 234. MEA Psoriasis Treatment, by Route of Administration USD Million (2023-2028)
  • Table 235. MEA Psoriasis Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 236. MEA Psoriasis Treatment, by Drug Class USD Million (2023-2028)
  • Table 237. Middle East Psoriasis Treatment, by Type USD Million (2023-2028)
  • Table 238. Middle East Psoriasis Treatment, by Route of Administration USD Million (2023-2028)
  • Table 239. Middle East Psoriasis Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 240. Middle East Psoriasis Treatment, by Drug Class USD Million (2023-2028)
  • Table 241. Africa Psoriasis Treatment, by Type USD Million (2023-2028)
  • Table 242. Africa Psoriasis Treatment, by Route of Administration USD Million (2023-2028)
  • Table 243. Africa Psoriasis Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 244. Africa Psoriasis Treatment, by Drug Class USD Million (2023-2028)
  • Table 245. North America Psoriasis Treatment, by Country USD Million (2023-2028)
  • Table 246. North America Psoriasis Treatment, by Type USD Million (2023-2028)
  • Table 247. North America Psoriasis Treatment, by Route of Administration USD Million (2023-2028)
  • Table 248. North America Psoriasis Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 249. North America Psoriasis Treatment, by Drug Class USD Million (2023-2028)
  • Table 250. United States Psoriasis Treatment, by Type USD Million (2023-2028)
  • Table 251. United States Psoriasis Treatment, by Route of Administration USD Million (2023-2028)
  • Table 252. United States Psoriasis Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 253. United States Psoriasis Treatment, by Drug Class USD Million (2023-2028)
  • Table 254. Canada Psoriasis Treatment, by Type USD Million (2023-2028)
  • Table 255. Canada Psoriasis Treatment, by Route of Administration USD Million (2023-2028)
  • Table 256. Canada Psoriasis Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 257. Canada Psoriasis Treatment, by Drug Class USD Million (2023-2028)
  • Table 258. Mexico Psoriasis Treatment, by Type USD Million (2023-2028)
  • Table 259. Mexico Psoriasis Treatment, by Route of Administration USD Million (2023-2028)
  • Table 260. Mexico Psoriasis Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 261. Mexico Psoriasis Treatment, by Drug Class USD Million (2023-2028)
  • Table 262. Research Programs/Design for This Report
  • Table 263. Key Data Information from Secondary Sources
  • Table 264. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Psoriasis Treatment: by Type USD Million (2017-2022)
  • Figure 5. Global Psoriasis Treatment: by Route of Administration USD Million (2017-2022)
  • Figure 6. Global Psoriasis Treatment: by Distribution Channel USD Million (2017-2022)
  • Figure 7. Global Psoriasis Treatment: by Drug Class USD Million (2017-2022)
  • Figure 8. South America Psoriasis Treatment Share (%), by Country
  • Figure 9. Asia Pacific Psoriasis Treatment Share (%), by Country
  • Figure 10. Europe Psoriasis Treatment Share (%), by Country
  • Figure 11. MEA Psoriasis Treatment Share (%), by Country
  • Figure 12. North America Psoriasis Treatment Share (%), by Country
  • Figure 13. Global Psoriasis Treatment share by Players 2022 (%)
  • Figure 14. Global Psoriasis Treatment share by Players (Top 3) 2022(%)
  • Figure 15. Global Psoriasis Treatment share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Johnson & Johnson Services, Inc. (U.S.) Revenue, Net Income and Gross profit
  • Figure 18. Johnson & Johnson Services, Inc. (U.S.) Revenue: by Geography 2022
  • Figure 19. Pfizer Inc. (U.S.) Revenue, Net Income and Gross profit
  • Figure 20. Pfizer Inc. (U.S.) Revenue: by Geography 2022
  • Figure 21. AbbVie Inc. (U.S.) Revenue, Net Income and Gross profit
  • Figure 22. AbbVie Inc. (U.S.) Revenue: by Geography 2022
  • Figure 23. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. Novartis AG (Switzerland) Revenue: by Geography 2022
  • Figure 25. LEO Pharma A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 26. LEO Pharma A/S (Denmark) Revenue: by Geography 2022
  • Figure 27. Merck & Co., Inc. (U.S.) Revenue, Net Income and Gross profit
  • Figure 28. Merck & Co., Inc. (U.S.) Revenue: by Geography 2022
  • Figure 29. UCB S.A. (Belgium) Revenue, Net Income and Gross profit
  • Figure 30. UCB S.A. (Belgium) Revenue: by Geography 2022
  • Figure 31. Sun Pharmaceutical Industries Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 32. Sun Pharmaceutical Industries Ltd. (India) Revenue: by Geography 2022
  • Figure 33. Amgen Inc. (U.S.) Revenue, Net Income and Gross profit
  • Figure 34. Amgen Inc. (U.S.) Revenue: by Geography 2022
  • Figure 35. Eli Lilly and Company (U.S.) Revenue, Net Income and Gross profit
  • Figure 36. Eli Lilly and Company (U.S.) Revenue: by Geography 2022
  • Figure 37. Evelo Biosciences, Inc. (U.S.) Revenue, Net Income and Gross profit
  • Figure 38. Evelo Biosciences, Inc. (U.S.) Revenue: by Geography 2022
  • Figure 39. Global Psoriasis Treatment: by Type USD Million (2023-2028)
  • Figure 40. Global Psoriasis Treatment: by Route of Administration USD Million (2023-2028)
  • Figure 41. Global Psoriasis Treatment: by Distribution Channel USD Million (2023-2028)
  • Figure 42. Global Psoriasis Treatment: by Drug Class USD Million (2023-2028)
  • Figure 43. South America Psoriasis Treatment Share (%), by Country
  • Figure 44. Asia Pacific Psoriasis Treatment Share (%), by Country
  • Figure 45. Europe Psoriasis Treatment Share (%), by Country
  • Figure 46. MEA Psoriasis Treatment Share (%), by Country
  • Figure 47. North America Psoriasis Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Johnson & Johnson Services, Inc. (U.S.)
  • Pfizer Inc. (U.S.)
  • AbbVie Inc. (U.S.)
  • Novartis AG (Switzerland)
  • LEO Pharma A/S (Denmark)
  • Merck & Co., Inc. (U.S.)
  • UCB S.A. (Belgium)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Amgen Inc. (U.S.)
  • Eli Lilly and Company (U.S.)
  • Evelo Biosciences, Inc. (U.S.)
Select User Access Type

Key Highlights of Report


May 2023 213 Pages 93 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Psoriasis Treatment Quantitative research analysis
Global Psoriasis Treatment Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Psoriasis Treatment Market are by type [Psoriatic Arthritis, Plaque Psoriasis and Others], by end use application [].
The Psoriasis Treatment Market is gaining popularity and expected to see strong valuation by 2028.
  • The high prevalence of skin disorders in the developed nations
  • Rapidly increasing geriatric population

Know More About Global Psoriasis Treatment Report?

Have a Query? Click Here

Other Related Reports

Beta blockers Comprehensive Study by Type (Non-selective antagonists, Selective β1-antagonists), Application (Abnormal Heart Rhythms, Hypertension), Generation (1st Generation, 2nd Generation, 3...
$ 3400
Narcolepsy Treatment Comprehensive Study by Type (Sodium Oxybate, Antidepressants, Central Nervous System Stimulants, Others), Application (Primary Narcolepsy with Cataplexy, Primary Narcolepsy witho...
$ 3750
Biosimilar Drug Comprehensive Study by Type (Recombinant Non-Glycosylated Proteins {Recombinant Human Growth Hormone, Insulin, Others}, Recombinant Glycosylated Proteins {Erythropoietin, Monoclonal A...
$ 3750
Sinusitis Drugs Comprehensive Study by Type (Analgesics, Antibiotics, Antihistamines, Corticosteroids, Decongestants, Sulphonamides), Application (Acute Sinusitis, Chronic Sinusitis), Treatment (Anti...
$ 3650
Barbiturate Drugs Comprehensive Study by Type (Phenobarbital, Amobarbital, Secobarbital, Pentobarbital, Others), Application (Insomnia, Seizures, Headaches, Others), Nature (Ultra-Short Acting Barbit...
$ 3750
Pigmented Villonodular Synovitis Drug Comprehensive Study by Type (Cabiralizumab, Emactuzumab, Mcs-110, Nilotinib, Others), Application (Reduces Swelling, Relieves Pain, Others), Distribution Channel...
$ 3650